


Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

UTSG:239/SHS

Serial No.

09/418,095

Applicant

John A. Copland, III, Slavisa Gasic, Randall J. Urban,
Melvyn Soloff

Filing Date:

October 14, 1999

Group:

1646

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
QN	A1	4,690,915	9/1/87	Rosenberg	514	2	8/8/85
↓	A2	5,199,942	4/6/93	Gillis	604	4	9/26/91
↓	A3	5,478,852	12/26/95	Olefsky <i>et al.</i>	514	369	8/23/94

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C1	Auersperg <i>et al.</i> , "Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes," <i>Lab. Invest.</i> 71:510-518, 1994.
↓	C2	Auersperg <i>et al.</i> , "Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer," <i>Am. J. Obstetr. Gynecol.</i> , 173:558-565, 1995.
↓	C3	Bao <i>et al.</i> , "Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas," <i>Hum. Gene Ther.</i> , 7:355-365, 1996.
↓	C4	Bass <i>et al.</i> , "Recombinant adenovirus-mediated gene transfer to genitourinary epithelium <i>in vitro</i> and <i>in vivo</i> ," <i>Cancer Gene Ther.</i> , 2:97-104, 1995.
↓	C5	Chinery <i>et al.</i> , "Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 ^{WAF1/CIP1} ," <i>Nature Medicine</i> 3:1233-1241, 1997.
↓	C6	Culver <i>et al.</i> , "In Vivo Gene Transfer with retroviral vector-producer cells for treatment of experimental brain tumors," <i>Science</i> , 256:1550-1552, 1992.
↓	C7	Dong <i>et al.</i> , "Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector," <i>Hum. Gene Ther.</i> , 7:319-331, 1996.

EXAMINER:

Quang Nguyen

DATE CONSIDERED:

08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSG:239/SHSSerial No.
09/418,095

Applicant

John A. Copland, III, Slavisa Gasic, Randall J. Urban,
Melvyn SoloffFiling Date:
October 14, 1999Gr up:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QN	C8	Dyck <i>et al.</i> , "Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer," <i>Int J Cancer</i> 69:429-436, 1996.
	C9	Elstner <i>et al.</i> , "Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells <i>in vitro</i> and in BNX mice," <i>Proc. Natl. Acad. Sci. USA</i> , 95:8806-8811, 1998.
	C10	Jacobs <i>et al.</i> , "Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and x-chromosome inactivation," <i>J Natl Cancer Inst.</i> , 84:1793-1798, 1992.
	C11	Jiang <i>et al.</i> , "PPAR γ agonists inhibit production of monocyte inflammatory cytokines," <i>Nature</i> , 391:82-86, 1998.
	C12	Kliwer and Wilson, "The nuclear receptor PPAR γ - bigger than fat," <i>Curr. Opin. Genet. Dev.</i> , 8:576-581, 1998.
	C13	Kliwer <i>et al.</i> , "Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors," <i>Nature</i> 358:771-774, 1992.
	C14	Kliwer <i>et al.</i> , "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors," <i>Proc. Natl Acad. Sci. USA</i> , 91:7355-7359, 1994.
	C15	Kubota <i>et al.</i> , "Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both <i>in vitro</i> and <i>in vivo</i> ," <i>Cancer Res</i> 58:3344-3352, 1998.
	C16	Lefebvre <i>et al.</i> , "Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC ^{min} /+ mice," <i>Nature Medicine</i> , 4: 1053-1057, 1998.
	C17	Lehmann <i>et al.</i> , "Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs," <i>J. Biological Chem.</i> , 272:3406-3410, 1997.
	C18	Mok <i>et al.</i> , "DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer," <i>Oncogene</i> 16:2381-2387, 1998.
✓	C19	Mok <i>et al.</i> , "Unifocal origin of advanced human epithelial ovarian cancers," <i>Cancer Res</i> 52:5119-5122, 1993.

EXAMINER:

Quang Nguyen

DATE CONSIDERED:

08/07/00

EXAMINER: INITIAL IF REFERENCE/CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>
--	---	--------------------------------

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QW	C20	Mueller <i>et al.</i> , "Terminal differentiation of human breast cancer through PPARY," <i>Molecular Cell</i> 1:465-470, 1998.
	C21	Warrel <i>et al.</i> , "Acute promyelocytic leukemia," <i>N Engl. J Med</i> 329:177-189, 1993.
	C22	Qazi and McGuire, "The treatment of epithelial ovarian cancer," <i>CA Cancer J Clin</i> 45:88-101, 1995.
	C23	Yu <i>et al.</i> , "Differential activation of peroxisome proliferator-activated receptors by eicosanoids," <i>J. Bio. Chem.</i> , 270:23975-23983, 1995.
	C24	Ricote <i>et al.</i> , "The peroxisome proliferator-activated receptor- γ is a negative regulator of macrophage activation," <i>Nature</i> , 391:79-85, 1998.
	C25	Rubinstein <i>et al.</i> , "Comparison of in vitro anticancer-drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines," <i>J. Natl. Cancer Inst.</i> , 82:1113-1120, 1990.
	C26	Saltiel and Olefsky, "Thiazolidinediones in the treatment of insulin resistance and type II diabetes," <i>Diabetes</i> , 45:1661-1669, 1996.
	C27	Sarraf <i>et al.</i> , "Differentiation and reversal of malignant changes in colon cancer through PPARY," <i>Nature Medicine</i> 4:1046-1052, 1998.
	C28	Sears <i>et al.</i> , "Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor γ ," <i>Mol. Cell Biol.</i> 16:3410-3418, 1996.
	C29	Sherr, "Cancer Cell Cycles," <i>Science</i> , 274:1672-1677, 1996.
	C30	Stauble <i>et al.</i> , "Modulation of activator protein-1 (AP-1) transcription factor and protein kinase C by hydrogen peroxide and d- α -tocopherol in vascular smooth muscle cells," <i>Eur. J. Biochem.</i> , 226:393-402, 1994.
	C31	Steiner <i>et al.</i> , "DI-alpha-tocopherol, a potent inhibitor of phorbol ester induced shape change of erythro- and megakaryoblastic leukemia cells," <i>J. Cellular Physiology</i> , 172:351-360, 1997.
	C32	Sugimura <i>et al.</i> , "Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor," <i>Biochemical and Biophysical Res. Communications</i> , 261:833-837, 1999.

EXAMINER:

Quang Nguyen

DATE CONSIDERED:

08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

List of Patents and Publications of Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSG:239/SHSSerial No.
09/418,095

Applicant

John A. Copland, III, Slavisa Gasic, Randall J. Urban,
Melvyn SoloffFiling Date:
October 14, 1999Group:
1646U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
QW	C33	Tontono et al., "mPPARY2: tissue-specific regulator of an adipocyte enhancer," <i>Nucleic Acids Res</i> 22:5628-5634, 1994.
	C34	Tontono et al., "Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARY and RXR α ," <i>Genes Dev</i> 8:1224-1234, 1994.
	C35	Tontono et al., "PPARY2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene," <i>Mol. Cell Biol.</i> 15:351-357, 1995.
	C36	Tontono et al., "Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid x receptor," <i>Proc Natl Acad Sci USA</i> 94:237-241, 1997.
	C37	Tsao et al., "Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas," <i>Gynecol Oncology</i> 48:5-10, 1993.
✓	C38	Turley et al., "Vitamin E succinate inhibits proliferation of bt-20 human breast cancer cells: increase binding of cyclin A negatively regulates E2F transactivation activity," <i>Cancer Research</i> , 57:2668-2675, 1997.

EXAMINER:

Quang Nguyen

DATE CONSIDERED:

08/07/00

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)